This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including more biotech buyout rumors, a hot new biotech start-up, and a new cosmetic drug.

In this video, health-care analyst David Williamson discusses a potential new solution to the double chin. Shares of Kythera (Nasdaq; KYTH) soared 25% on the news of a successful phase 3 trial for ATX-101, the sole drug in its pipeline.

Watch Market Checkup and find out more about the exciting cosmetic drug space, including a closer look at Botox maker Allergan (NYSE:AGN), and whether investors should jump aboard the Kythera bandwagon. 

Follow David on Twitter: @MotleyDavid.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavidMax Macaluso, Ph.D. has no position in any stocks mentioned.

The Motley Fool owns shares of Microsoft. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.